IL-1 in aging and pathologies of hematopoietic stem cells

2.

Caiado

F

,

Pietras

EM

,

Manz

MG

.

Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection

.

J Exp Med

.

2021

;

218

(

7

):

e20201541

.

3.

Pietras

EM

.

Inflammation: a key regulator of hematopoietic stem cell fate in health and disease

.

Blood

.

2017

;

130

(

15

):

1693

-

1698

.

4.

Trumpp

A

,

Essers

M

,

Wilson

A

.

Awakening dormant haematopoietic stem cells

.

Nat Rev Immunol

.

2010

;

10

(

3

):

201

-

209

.

5.

Medzhitov

R

.

Origin and physiological roles of inflammation

.

Nature

.

2008

;

454

(

7203

):

428

-

435

.

6.

Dinarello

CA

.

Overview of the IL-1 family in innate inflammation and acquired immunity

.

Immunol Rev

.

2018

;

281

(

1

):

8

-

27

.

7.

Garlanda

C

,

Dinarello

CA

,

Mantovani

A

.

The interleukin-1 family: back to the future

.

Immunity

.

2013

;

39

(

6

):

1003

-

1018

.

8.

Mantovani

A

,

Dinarello

CA

,

Molgora

M

,

Garlanda

C

.

Interleukin-1 and related cytokines in the regulation of inflammation and immunity

.

Immunity

.

2019

;

50

(

4

):

778

-

795

.

9.

Rider

P

,

Carmi

Y

,

Guttman

O

, et al.

IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation

.

J Immunol

.

2011

;

187

(

9

):

4835

-

4843

.

10.

Boraschi

D

.

What is IL-1 for? the functions of interleukin-1 across evolution

.

Front Immunol

.

2022

;

13

:

872155

.

11.

Eislmayr

K

,

Bestehorn

A

,

Morelli

L

, et al.

Nonredundancy of IL-1α and IL-1β is defined by distinct regulation of tissues orchestrating resistance versus tolerance to infection

.

Sci Adv

.

2022

;

8

(

9

):

eabj7293

.

12.

Weber

A

,

Wasiliew

P

,

Kracht

M

.

Interleukin-1 (IL-1) pathway

.

Sci Signal

.

2010

;

3

(

105

):

cm1

.

13.

Aksentijevich

I

,

Masters

SL

,

Ferguson

PJ

, et al.

An autoinflammatory disease with deficiency of the interleukin-1–receptor antagonist

.

N Engl J Med

.

2009

;

360

(

23

):

2426

-

2437

.

14.

Wang

Y

,

Wang

J

,

Zheng

W

, et al.

Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design

.

Immunity

.

2023

;

56

(

7

):

1485

-

1501.e7

.

15.

Franceschi

C

,

Campisi

J

.

Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases

.

J Gerontol A Biol Sci Med Sci

.

2014

;

69

(

suppl 1

):

S4

-

S9

.

16.

Kovtonyuk

LV

,

Fritsch

K

,

Feng

X

,

Manz

MG

,

Takizawa

H

.

Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment

.

Front Immunol

.

2016

;

7

:

502

.

17.

Teissier

T

,

Boulanger

E

,

Cox

LS

.

Interconnections between inflammageing and immunosenescence during ageing

.

Cells

.

2022

;

11

(

3

):

359

.

18.

Kovtonyuk

LV

,

Caiado

F

,

Garcia-Martin

S

, et al.

IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice

.

Blood

.

2022

;

139

(

1

):

44

-

58

.

19.

Mitchell

CA

,

Verovskaya

EV

,

Calero-Nieto

FJ

, et al.

Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing

.

Nat Cell Biol

.

2023

;

25

(

1

):

30

-

41

.

20.

Frisch

BJ

,

Hoffman

CM

,

Latchney

SE

, et al.

Aged marrow macrophages expand platelet-biased hematopoietic stem cells via interleukin-1B

.

JCI Insight

.

2019

;

5

(

10

):

e124213

.

21.

Pioli

PD

,

Casero

D

,

Montecino-Rodriguez

E

,

Morrison

SL

,

Dorshkind

K

.

Plasma cells are obligate effectors of enhanced myelopoiesis in aging bone marrow

.

Immunity

.

2019

;

51

(

2

):

351

-

366.e6

.

22.

Luis

TC

,

Barkas

N

,

Carrelha

J

, et al.

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner

.

Nat Commun

.

2023

;

14

(

1

):

6062

.

23.

Li

S

,

Yao

JC

,

Oetjen

KA

, et al.

IL-1β expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function

.

Blood

.

2022

;

140

(

14

):

1607

-

1620

.

24.

Funk

MC

,

Zhou

J

,

Boutros

M

.

Ageing, metabolism and the intestine

.

EMBO Rep

.

2020

;

21

(

7

):

e50047

.

25.

Zeng

X

,

Li

X

,

Li

X

, et al.

Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation

.

Blood

.

2023

;

141

(

14

):

1691

-

1707

.

26.

van der Meer

JW

,

Barza

M

,

Wolff

SM

,

Dinarello

CA

.

A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection

.

Proc Natl Acad Sci U S A

.

1988

;

85

(

5

):

1620

-

1623

.

27.

Damia

G

,

Komschlies

KL

,

Futami

H

, et al.

Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities

.

Cancer Res

.

1992

;

52

(

15

):

4082

-

4089

.

28.

Pietras

EM

,

Mirantes-Barbeito

C

,

Fong

S

, et al.

Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal

.

Nat Cell Biol

.

2016

;

18

(

6

):

607

-

618

.

29.

Caiado

F

,

Kovtonyuk

LV

,

Gonullu

NG

,

Fullin

J

,

Boettcher

S

,

Manz

MG

.

Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling

.

Blood

.

2023

;

141

(

8

):

886

-

903

.

30.

Villatoro

A

,

Cuminetti

V

,

Bernal

A

, et al.

Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation

.

Nat Commun

.

2023

;

14

(

1

):

12

.

31.

Ueda

Y

,

Cain

DW

,

Kuraoka

M

,

Kondo

M

,

Kelsoe

G

.

IL-1R type I-dependent hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia

.

J Immunol

.

2009

;

182

(

10

):

6477

-

6484

.

32.

Weisser

M

,

Demel

UM

,

Stein

S

, et al.

Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions

.

J Allergy Clin Immunol

.

2016

;

138

(

1

):

219

-

228.e9

.

33.

Rabe

JL

,

Hernandez

G

,

Chavez

JS

,

Mills

TS

,

Nerlov

C

,

Pietras

EM

.

CD34 and EPCR coordinately enrich functional murine hematopoietic stem cells under normal and inflammatory conditions

.

Exp Hematol

.

2020

;

81

:

1

-

15.e6

.

34.

Chavez

JS

,

Rabe

JL

,

Loeffler

D

, et al.

PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress

.

J Exp Med

.

2021

;

218

(

6

):

e20201169

.

35.

Staber

PB

,

Zhang

P

,

Ye

M

, et al.

Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells

.

Mol Cell

.

2013

;

49

(

5

):

934

-

946

.

36.

Kueh

HY

,

Champhekar

A

,

Nutt

SL

,

Elowitz

MB

,

Rothenberg

EV

.

Positive feedback between PU.1 and the cell cycle controls myeloid differentiation

.

Science

.

2013

;

341

(

6146

):

670

-

673

.

37.

Guillamot

M

,

Ouazia

D

,

Dolgalev

I

, et al.

The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation

.

Nat Immunol

.

2019

;

20

(

9

):

1196

-

1207

.

38.

Hernandez

G

,

Mills

TS

,

Rabe

JL

, et al.

Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis

.

Haematologica

.

2020

;

105

(

3

):

585

-

597

.

39.

Al Zouabi

L

,

Bardin

AJ

.

Stem cell DNA damage and genome mutation in the context of aging and cancer initiation

.

Cold Spring Harb Perspect Biol

.

2020

;

12

(

10

):

a036210

.

40.

Osorio

FG

,

Rosendahl Huber

A

,

Oka

R

, et al.

Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis

.

Cell Rep

.

2018

;

25

(

9

):

2308

-

2316.e4

.

41.

Lee-Six

H

,

Øbro

NF

,

Shepherd

MS

, et al.

Population dynamics of normal human blood inferred from somatic mutations

.

Nature

.

2018

;

561

(

7724

):

473

-

478

.

42.

Mitchell

E

,

Spencer Chapman

M

,

Williams

N

, et al.

Clonal dynamics of haematopoiesis across the human lifespan

.

Nature

.

2022

;

606

(

7913

):

343

-

350

.

43.

Chin

DWL

,

Yoshizato

T

,

Virding Culleton

S

, et al.

Aged healthy mice acquire clonal hematopoiesis mutations

.

Blood

.

2022

;

139

(

4

):

629

-

634

.

44.

Boettcher

S

,

Ebert

BL

.

Clonal hematopoiesis of indeterminate potential

.

J Clin Oncol

.

2019

;

37

(

5

):

419

-

422

.

45.

Steensma

DP

,

Bejar

R

,

Jaiswal

S

, et al.

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

.

Blood

.

2015

;

126

(

1

):

9

-

16

.

46.

Genovese

G

,

Kähler

AK

,

Handsaker

RE

, et al.

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

.

N Engl J Med

.

2014

;

371

(

26

):

2477

-

2487

.

47.

Jaiswal

S

,

Fontanillas

P

,

Flannick

J

, et al.

Age-related clonal hematopoiesis associated with adverse outcomes

.

N Engl J Med

.

2014

;

371

(

26

):

2488

-

2498

.

48.

Xie

M

,

Lu

C

,

Wang

J

, et al.

Age-related mutations associated with clonal hematopoietic expansion and malignancies

.

Nat Med

.

2014

;

20

(

12

):

1472

-

1478

.

49.

Desai

P

,

Mencia-Trinchant

N

,

Savenkov

O

, et al.

Somatic mutations precede acute myeloid leukemia years before diagnosis

.

Nat Med

.

2018

;

24

(

7

):

1015

-

1023

.

50.

Abelson

S

,

Collord

G

,

Ng

SWK

, et al.

Prediction of acute myeloid leukaemia risk in healthy individuals

.

Nature

.

2018

;

559

(

7714

):

400

-

404

.

51.

Florez

MA

,

Tran

BT

,

Wathan

TK

,

DeGregori

J

,

Pietras

EM

,

King

KY

.

Clonal hematopoiesis: mutation-specific adaptation to environmental change

.

Cell Stem Cell

.

2022

;

29

(

6

):

882

-

904

.

52.

Young

AL

,

Challen

GA

,

Birmann

BM

,

Druley

TE

.

Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults

.

Nat Commun

.

2016

;

7

:

12484

.

53.

Bick

AG

,

Weinstock

JS

,

Nandakumar

SK

, et al.

Inherited causes of clonal haematopoiesis in 97,691 whole genomes

.

Nature

.

2020

;

586

(

7831

):

763

-

768

.

54.

Leoni

C

,

Montagner

S

,

Rinaldi

A

, et al.

Dnmt3a restrains mast cell inflammatory responses

.

Proc Natl Acad Sci U S A

.

2017

;

114

(

8

):

E1490

-

E1499

.

55.

Sano

S

,

Oshima

K

,

Wang

Y

,

Katanasaka

Y

,

Sano

M

,

Walsh

K

.

CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease

.

Circ Res

.

2018

;

123

(

3

):

335

-

341

.

56.

Sano

S

,

Oshima

K

,

Wang

Y

, et al.

Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome

.

J Am Coll Cardiol

.

2018

;

71

(

8

):

875

-

886

.

57.

Fuster

JJ

,

MacLauchlan

S

,

Zuriaga

MA

, et al.

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

.

Science

.

2017

;

355

(

6327

):

842

-

847

.

58.

Zhang

Q

,

Zhao

K

,

Shen

Q

, et al.

Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

.

Nature

.

2015

;

525

(

7569

):

389

-

393

.

59.

Cull

AH

,

Snetsinger

B

,

Buckstein

R

,

Wells

RA

,

Rauh

MJ

.

Tet2 restrains inflammatory gene expression in macrophages

.

Exp Hematol

.

2017

;

55

:

56

-

70.e13

.

60.

Wang

W

,

Liu

W

,

Fidler

T

, et al.

Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice

.

Circ Res

.

2018

;

123

(

11

):

e35

-

e47

.

61.

Ito

S

,

D'Alessio

AC

,

Taranova

OV

,

Hong

K

,

Sowers

LC

,

Zhang

Y

.

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

.

Nature

.

2010

;

466

(

7310

):

1129

-

1133

.

62.

Nazha

A

,

Komrokji

R

,

Meggendorfer

M

, et al.

Personalized prediction model to risk stratify patients with myelodysplastic syndromes

.

J Clin Oncol

.

2021

;

39

(

33

):

3737

-

3746

.

63.

Moran-Crusio

K

,

Reavie

L

,

Shih

A

, et al.

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

.

Cancer Cell

.

2011

;

20

(

1

):

11

-

24

.

64.

Ko

M

,

Bandukwala

HS

,

An

J

, et al.

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

.

Proc Natl Acad Sci U S A

.

2011

;

108

(

35

):

14566

-

14571

.

65.

Svensson

EC

,

Madar

A

,

Campbell

CD

, et al.

TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial

.

JAMA Cardiol

.

2022

;

7

(

5

):

521

-

528

.

66.

Burns

SS

,

Kumar

R

,

Pasupuleti

SK

,

So

K

,

Zhang

C

,

Kapur

R

.

Il-1r1 drives leukemogenesis induced by Tet2 loss

.

Leukemia

.

2022

;

36

(

10

):

2531

-

2534

.

67.

McClatchy

J

,

Strogantsev

R

,

Wolfe

E

, et al.

Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells

.

Nat Commun

.

2023

;

14

(

1

):

8102

.

68.

Cordua

S

,

Kjaer

L

,

Skov

V

,

Pallisgaard

N

,

Hasselbalch

HC

,

Ellervik

C

.

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

.

Blood

.

2019

;

134

(

5

):

469

-

479

.

69.

Baxter

EJ

,

Scott

LM

,

Campbell

PJ

, et al.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

.

Lancet

.

2005

;

365

(

9464

):

1054

-

1061

.

70.

Kralovics

R

,

Passamonti

F

,

Buser

AS

, et al.

A gain-of-function mutation of JAK2 in myeloproliferative disorders

.

N Engl J Med

.

2005

;

352

(

17

):

1779

-

1790

.

71.

Levine

RL

,

Wadleigh

M

,

Cools

J

, et al.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

.

Cancer Cell

.

2005

;

7

(

4

):

387

-

397

.

72.

Mullally

A

,

Lane

SW

,

Ball

B

, et al.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

.

Cancer Cell

.

2010

;

17

(

6

):

584

-

596

.

73.

Kent

DG

,

Li

J

,

Tanna

H

, et al.

Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion

.

PLoS Biol

.

2013

;

11

(

6

):

e1001576

.

74.

Rai

S

,

Grockowiak

E

,

Hansen

N

, et al.

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm

.

Nat Commun

.

2022

;

13

(

1

):

5346

.

75.

Rahman

MF

,

Yang

Y

,

Le

BT

, et al.

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

.

Nat Commun

.

2022

;

13

(

1

):

5347

.

76.

Rai

S

,

Zhang

Y

,

Grockowiak

E

, et al.

IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells

.

Blood Adv

.

2024

;

8

(

5

):

1234

-

1249

.

77.

Arranz

L

,

Sánchez-Aguilera

A

,

Martín-Pérez

D

, et al.

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms

.

Nature

.

2014

;

512

(

7512

):

78

-

81

.

78.

Gu

X

,

Ebrahem

Q

,

Mahfouz

RZ

, et al.

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates

.

J Clin Invest

.

2018

;

128

(

10

):

4260

-

4279

.

79.

Guo

H

,

Ma

O

,

Speck

NA

,

Friedman

AD

.

Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis

.

Blood

.

2012

;

119

(

19

):

4408

-

4418

.

80.

Cancer Genome Atlas Research Network

,

Ley

TJ

,

Miller

C

, et al.

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

.

N Engl J Med

.

2013

;

368

(

22

):

2059

-

2074

.

81.

Pabst

T

,

Mueller

BU

,

Harakawa

N

, et al.

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia

.

Nat Med

.

2001

;

7

(

4

):

444

-

451

.

82.

Perrotti

D

,

Cesi

V

,

Trotta

R

, et al.

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2

.

Nat Genet

.

2002

;

30

(

1

):

48

-

58

.

83.

Zheng

R

,

Friedman

AD

,

Levis

M

,

Li

L

,

Weir

EG

,

Small

D

.

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression

.

Blood

.

2004

;

103

(

5

):

1883

-

1890

.

84.

Higa

KC

,

Goodspeed

A

,

Chavez

JS

, et al.

Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors

.

J Exp Med

.

2021

;

218

(

6

):

e20200560

.

85.

Hormaechea-Agulla

D

,

Matatall

KA

,

Le

DT

, et al.

Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling

.

Cell Stem Cell

.

2021

;

28

(

8

):

1428

-

1442.e6

.

86.

Kristinsson

SY

,

Björkholm

M

,

Hultcrantz

M

,

Derolf

ÅR

,

Landgren

O

,

Goldin

LR

.

Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes

.

J Clin Oncol

.

2011

;

29

(

21

):

2897

-

2903

.

87.

Kristinsson

SY

,

Landgren

O

,

Samuelsson

J

,

Björkholm

M

,

Goldin

LR

.

Autoimmunity and the risk of myeloproliferative neoplasms

.

Haematologica

.

2010

;

95

(

7

):

1216

-

1220

.

88.

Arranz

L

,

Arriero

MdM

,

Villatoro

A

.

Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications

.

Blood Rev

.

2017

;

31

(

5

):

306

-

317

.

89.

Ren

R

.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

.

Nat Rev Cancer

.

2005

;

5

(

3

):

172

-

183

.

90.

Wetzler

M

,

Kurzrock

R

,

Estrov

Z

, et al.

Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: Clinical and prognostic correlates

.

Blood

.

1994

;

84

(

9

):

3142

-

3147

.

91.

Zhang

B

,

Ho

YW

,

Huang

Q

, et al.

Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia

.

Cancer Cell

.

2012

;

21

(

4

):

577

-

592

.

92.

Zhao

K

,

Yin

LL

,

Zhao

DM

, et al.

IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients

.

Int J Clin Exp Med

.

2014

;

7

(

12

):

4787

-

4798

.

93.

Järås

M

,

Johnels

P

,

Hansen

N

, et al.

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

.

Proc Natl Acad Sci U S A

.

2010

;

107

(

37

):

16280

-

16285

.

94.

Ågerstam

H

,

Hansen

N

,

von Palffy

S

, et al.

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

.

Blood

.

2016

;

128

(

23

):

2683

-

2693

.

95.

Lee

CR

,

Kang

JA

,

Kim

HE

,

Choi

Y

,

Yang

T

,

Park

SG

.

Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance

.

FEBS Lett

.

2016

;

590

(

3

):

358

-

368

.

96.

Estrov

Z

,

Kurzrock

R

,

Wetzler

M

, et al.

Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity

.

Blood

.

1991

;

78

(

6

):

1476

-

1484

.

97.

Zhang

B

,

Chu

S

,

Agarwal

P

, et al.

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells

.

Blood

.

2016

;

128

(

23

):

2671

-

2682

.

98.

Skoda

RC

,

Duek

A

,

Grisouard

J

.

Pathogenesis of myeloproliferative neoplasms

.

Exp Hematol

.

2015

;

43

(

8

):

599

-

608

.

99.

Vaidya

R

,

Gangat

N

,

Jimma

T

, et al.

Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis

.

Am J Hematol

.

2012

;

87

(

11

):

1003

-

1005

.

100.

Sallman

DA

,

List

A

.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

.

Blood

.

2019

;

133

(

10

):

1039

-

1048

.

101.

Basiorka

AA

,

McGraw

KL

,

Eksioglu

EA

, et al.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

.

Blood

.

2016

;

128

(

25

):

2960

-

2975

.

102.

Barreyro

L

,

Will

B

,

Bartholdy

B

, et al.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS

.

Blood

.

2012

;

120

(

6

):

1290

-

1298

.

103.

Rhyasen

GW

,

Bolanos

L

,

Fang

J

, et al.

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

.

Cancer Cell

.

2013

;

24

(

1

):

90

-

104

.

104.

Schneider

M

,

Rolfs

C

,

Trumpp

M

, et al.

Activation of distinct inflammatory pathways in subgroups of LR-MDS

.

Leukemia

.

2023

;

37

(

8

):

1709

-

1718

.

105.

Preisler

H

,

Raza

A

,

Kukla

C

,

Larson

R

,

Goldberg

J

,

Browman

G

.

Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter]

.

Blood

.

1991

;

78

(

3

):

849

-

850

.

106.

Grauers Wiktorin

H

,

Aydin

E

,

Christenson

K

, et al.

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance

.

Oncoimmunology

.

2021

;

10

(

1

):

1944538

.

107.

Hoang

T

,

Haman

A

,

Goncalves

O

, et al.

Interleukin 1 enhances growth factor-dependent proliferation of the clonogenic cells in acute myeloblastic leukemia and of normal human primitive hemopoietic precursors

.

J Exp Med

.

1988

;

168

(

2

):

463

-

474

.

108.

Griffin

J

,

Rambaldi

A

,

Vellenga

E

,

Young

DC

,

Ostapovicz

D

,

Cannistra

SA

.

Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors

.

Blood

.

1987

;

70

(

4

):

1218

-

1221

.

109.

Cozzolino

F

,

Rubartelli

A

,

Aldinucci

D

, et al.

Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells

.

Proc Natl Acad Sci U S A

.

1989

;

86

(

7

):

2369

-

2373

.

110.

Turzanski

J

,

Grundy

M

,

Russell

NH

,

Pallis

M

.

Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways

.

Leukemia

.

2004

;

18

(

10

):

1662

-

1670

.

111.

Hosseini

MM

,

Kurtz

SE

,

Abdelhamed

S

, et al.

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

.

Leukemia

.

2018

;

32

(

11

):

2374

-

2387

.

112.

Carey

A

,

Edwards

DK

,

Eide

CA

, et al.

Identification of Interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia

.

Cell Rep

.

2017

;

18

(

13

):

3204

-

3218

.

113.

Mitchell

K

,

Barreyro

L

,

Todorova

TI

, et al.

IL1RAP potentiates multiple oncogenic signaling pathways in AML

.

J Exp Med

.

2018

;

215

(

6

):

1709

-

1727

.

114.

De Boer

B

,

Sheveleva

S

,

Apelt

K

, et al.

The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis

.

Haematologica

.

2021

;

106

(

12

):

3067

-

3078

.

115.

Ågerstam

H

,

Karlsson

C

,

Hansen

N

, et al.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

.

Proc Natl Acad Sci U S A

.

2015

;

112

(

34

):

10786

-

10791

.

116.

Trad

R

,

Warda

W

,

Alcazer

V

, et al.

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

.

J Immunother Cancer

.

2022

;

10

(

7

):

e004222

.

117.

Fidler

TP

,

Xue

C

,

Yalcinkaya

M

, et al.

The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis

.

Nature

.

2021

;

592

(

7853

):

296

-

301

.

118.

Rauch

PJ

,

Gopakumar

J

,

Silver

AJ

, et al.

Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes

.

Nat Cardiovasc Res

.

2023

;

2

(

9

):

805

-

818

.

119.

Kessler

MD

,

Damask

A

,

O'Keeffe

S

, et al.

Common and rare variant associations with clonal haematopoiesis phenotypes

.

Nature

.

2022

;

612

(

7939

):

301

-

309

.